sandalwood

Key Highlights

In 2025, the Chinese weight loss drug market witnessed two developments that were largely unforeseen at the beginning of the year: the overall growth rate of weight loss drugs (including GLP-1s and Orlistat) on e-commerce channels reached 102%, nearly 10 times that of hospital channels; and Tirzepatide overtook Semaglutide, capturing a 44% share of the e-commerce market.

This is not merely a case of individual products rising or falling, but rather a systemic shift in the market's channel logic, competitive landscape, and consumer behavior, all occurring within a single year.

At the China OTC Industry Development Conference held in Wuzhen on April 13th, Sandalwood and IQVIA jointly released the "2026 China Weight Loss Drug Market Panorama Insight Report."

Sarah Hu, VP of Emerging Business at Sandalwood, delivered a keynote speech based on the report. Leveraging omni-channel data covering hospitals, retail pharmacies, primary care, and four major e-commerce platforms, this report is the first to systematically dissect the growth logic, channel migration trends, and spillover effects of the Chinese weight loss drug market from a consumer goods analysis perspective.

This article distills the core findings of the report for industry reference.

Channel Landscape: E-commerce is Closing the Gap with Hospitals in a Historic Catch-up

Over the past three years, the channel structure of China's weight loss drug market has undergone a fundamental transformation.

In 2023, the hospital channel was roughly 4 times the size of e-commerce, reflecting a clear prescription-dominated logic. However, by Q4 2025, this gap had narrowed significantly—e-commerce reached a quarterly volume of 1.8 billion RMB, compared to 2.1 billion RMB for hospitals, leaving a mere 15% difference. Based on current growth trends, e-commerce is projected to overtake hospitals for the first time in the first half of 2026.

• 2025 Growth Rates: E-commerce: +102% | Hospitals: +11% | Pharmacies: +88%
• GLP-1 E-commerce Volume: 2.871 billion RMB (+169% YoY)

Driving this shift is not just a migration of online purchasing habits. A wave of new users—who have never stepped foot in a hospital—is completing their entire medication decision-making process via internet hospital consultations and e-commerce platforms. E-commerce is creating incremental demand, rather than simply cannibalizing the existing hospital market.

For marketing and commercial teams, this means the logic of channel resource allocation needs to be re-evaluated. While academic promotion in hospitals remains important, brand building and user operations in the e-commerce channel are no longer optional.

Particularly noteworthy are the decision-making motivations of e-commerce users. Based on big data analysis of consumer reviews in 2025, 82% of GLP-1 e-commerce buyers prioritize weight loss/body management, while only 18% cite blood sugar control/diabetes as their primary motivation. High-frequency keywords show that weight loss terms like "appetite," "weight loss," and "slimmed down" appear far more frequently than medical terms like "blood sugar" or "hypoglycemic." This implies that the consumption driver for GLP-1s on e-commerce is essentially closer to a consumer product than a prescription drug.

This leads to a critical insight: hospital patients and e-commerce users are two fundamentally different groups. Hospitals focus on medical needs, doctor-led prescriptions, and insurance-bound repurchasing; e-commerce focuses on weight management, consumer autonomy, experience-driven repurchasing, and higher price sensitivity. Hospitals and e-commerce are not the same battlefield; they require distinct operational logic and content strategies.

Competitive Landscape: 2026 as the Watershed for Pricing Structures

The e-commerce landscape in 2025 was defined by a distinct duopoly: Tirzepatide led with a 44% share, followed closely by Semaglutide at 40%, while the domestic innovator Mazdutide quickly carved out a 6% niche. Notably, despite Tirzepatide being priced over 50% higher than Semaglutide, it still managed to overtake it in market share, fully validating that consumers are willing to pay a premium for superior efficacy.

Another counter-intuitive finding is that Orlistat has not been squeezed out by GLP-1s. In 2025, Orlistat achieved an omni-channel growth rate of +42%, slightly outpacing the +35% growth of GLP-1s. This indicates that the growth in the weight loss drug market is not a zero-sum game. Instead, it is an inclusive expansion driven by the activation of overall weight loss demand—consumers across different price points and medication pathways are entering the market simultaneously.

However, this landscape is set to face a fundamental shock in 2026.

The compound patent for Semaglutide expires in March 2026, and as of early 2026, more than 10 domestic manufacturers have entered the application acceptance stage for generics (according to NMPA public announcements). The influx of generics, coupled with proactive price cuts by originator brands as a defensive measure, will trigger a disruptive reconstruction of the pricing system within the next 12 months.

The report predicts the market will gradually form a three-tier competitive ecosystem:

• Originator Brand Tier: Relying on brand equity and hospital prescription relationships to defend premium pricing space.
• Domestic Innovation Tier: Competing for the mid-range market through National Reimbursement Drug List (NRDL) positioning and dual-indication narratives.
• Generic Mass-Market Tier: Penetrating chain pharmacies and e-commerce platforms through aggressive price strategies.

For brand owners, the current window of opportunity is shorter than most anticipate. Completing user perception building and establishing channel barriers before generics are officially approved is the most urgent strategic imperative for 2026.

Consumer Behavior: Medication Pathways are Catalyzing Systemic Spillover Consumption

The impact of the weight loss drug market has extended far beyond the pharmaceutical category itself.

The report conducted a consumption pathway analysis of the entire GLP-1 medication journey, identifying spillover consumption nodes across four key stages: the pre-medication information decision phase, the supply procurement during the initiation phase, nutrition and appearance management during the maintenance phase, and repurchase drivers at the discontinuation node.

The report performed a correlation test on six major accompanying categories (Spearman rank correlation, excluding the Q4 2025 promotional season, n=6), revealing a three-tier evidence structure:

Data shows that the Spearman correlation coefficient between GLP-1 injection e-commerce sales and the growth of injection consumables (insulin pen needles) is as high as ρ=0.94 (p=0.005). This constitutes the strongest联动 (linkage) evidence at a statistical level—since needles are essential consumables for GLP-1 injections, their growth rates are highly synchronized.

Body fat scales (ρ=0.60) and anti-hair loss shampoos (ρ=0.43) also exhibit positive co-movement trends. Notably, in 2025, e-commerce growth for anti-hair loss shampoo reached +42%, body fat scales +29%, and insulin pen needles +18%. The growth rhythm of all three categories aligns closely with the acceleration phase of GLP-1 penetration.

For broad health consumer brands, this spillover effect has evolved from a data phenomenon into a verifiable structural opportunity. Category stickiness stems from genuine medication-companion demand, naturally scaling up alongside the expansion of the GLP-1 user base.

Market Potential: Catching Up on Penetration is the Most Certain Mid-Term Theme

According to the BMI standards for Chinese adults (Overweight: BMI ≥ 24; Obese: BMI ≥ 28), approximately 620 million people in China are either overweight or obese. The weight loss drug market in China was valued at 14.1 billion RMB in 2025 and is projected to grow to 20.4 billion RMB by 2027, indicating that the penetration rate of GLP-1 drugs is still in a very early stage.

Compared to mature markets that have already established scaled medication habits, there is a significant structural gap between the scale of demand in China and the current level of penetration. The report judges that the continuous rise in penetration rates will be the most certain growth theme for China's weight loss drug market from 2026 to 2030.

Summary

E-commerce overtaking hospitals, generics reconstructing the pricing system, and spillover consumption becoming an opportunity for new categories—these three structural shifts are happening simultaneously. For pharmaceutical brands, retail channels, and broad health consumer brands, understanding the speed and depth of these changes is the prerequisite for formulating 2026 strategies.

In this window of rapidly evolving landscapes, data is the scarcest competitive element. Whoever can see the true temperature of the market faster and more accurately will gain a half-step advantage in strategic decision-making.